CordenPharma to Produce Eli Lilly's Weight Loss Drug Componen

Pharmaceutical giant Eli Lilly (

The burgeoning demand for weight loss pharmaceuticals is providing a substantial impetus to contract development and manufacturing organizations (CDMOs) such as CordenPharma. This trend compensates for the dip in COVID-19 related contracts for these entities. In a parallel move, Novo Nordisk, a competitor to Eli Lilly, is ramping up the production of its obesity drug, Wegovy, which shares the same therapeutic class as Mounjaro. Both drugs, known as GLP-1 receptor agonists, initially formulated for diabetes treatment, act by delaying digestion and curbing appetite.

With projections placing the potential worth of the obesity drug market at a staggering $100 billion over the forthcoming decade, pharmaceutical companies are keenly capitalizing on this opportunity. A testament to this burgeoning interest is Eli Lilly's soaring market value, which has witnessed a surge of 62.5% this year alone, primarily driven by the high demand for Mounjaro.

As of late, CordenPharma disclosed the successful expansion of its Boulder facility, which will now accommodate an additional 60 staff members. Notably, during the COVID-19 pandemic, this facility was instrumental in supplying Moderna (MRNA) with significant quantities of lipids essential for its vaccine production.